John R Hamill

John R. Hamill serves as Chief Contracting Officer at the National Institute on Drug Abuse, where he oversees the full lifecycle of federal acquisitions to support the agency’s mission of advancing scientific research on substance use and addiction. In this leadership role, he ensures compliance with federal procurement regulations while strategically aligning contracting activities with NIDA’s research priorities. He manages a diverse portfolio of acquisitions, including clinical research services, data analytics platforms, laboratory equipment, and behavioral health support systems, often involving complex, multi-year task orders and research consortia. His expertise spans both commercial and non-traditional vendor engagement, ensuring that scientific needs are met through agile, compliant contracting solutions. While specific contractor relationships are not publicly enumerated, Hamill’s procurement approach emphasizes performance-based outcomes and technical excellence, engaging a broad spectrum of vendors—from large research institutions and biomedical contractors to specialized service providers in neuroscience and data management. His working relationships are characterized by a focus on long-term partnership, rigorous source selection, and transparent competition, fostering innovation while maintaining strict adherence to federal acquisition standards. Hamill’s contracting patterns reflect a strong preference for open competition, with 100% of awards issued without set-aside designations. This indicates a deliberate strategy prioritizing technical capability and scientific merit over socioeconomic classifications, though small business participation may still occur organically through full and open competitions. His approach underscores a commitment to selecting the most qualified offerors regardless of size or status, consistent with NIDA’s mission-driven procurement philosophy. His primary procurement focus lies in NAICS categories related to scientific research and development, clinical trial management, behavioral health services, and advanced data systems. He routinely procures specialized services in neuroimaging, longitudinal study support, electronic data capture, and substance use disorder intervention technologies, demonstrating deep familiarity with the technical and regulatory demands of federally funded biomedical research.